Penetration of doripenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 532-535

  Burian, Bernhard ^a   Zeitlinger, Markus ^a   Donath, Oliver ^b   Reznicek, Gottfried ^b   Sauermann, Robert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DORIPENEM;

ADULT; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG SALIVA LEVEL; DRUG TISSUE LEVEL; EXTRACELLULAR SPACE; HUMAN; HUMAN EXPERIMENT; MALE; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SALIVA; SINGLE DRUG DOSE; SKELETAL MUSCLE; SUBCUTANEOUS FAT; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CARBAPENEMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EXTRACELLULAR FLUID; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICRODIALYSIS; MUSCLE, SKELETAL; PLASMA; SALIVA; SUBCUTANEOUS FAT; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 84455173000     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05506-11     Document Type: Article

References (26)

1. Alvarez-Lerma F, Grau S, Ferrandez O. 2009. Characteristics of doripenem: a new broad-spectrum antibiotic. Drug Des. Devel. Ther. 3:173-190.
2. Betriu C, et al. 2010. Activity of doripenem against extended-spectrum beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates. Eur. J. Clin. Microbiol. Infect. Dis. 29:1179-1181.
3. Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. 2005. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob. Agents Chemother. 49:3944-3947. (Pubitemid 41233056)
4. Bretonnière C, et al. 2010. Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem. J. Antimicrob. Chemother. 65:2423-2427.
5. 14C]doripenem after a single 500-milligram intravenous infusion in healthy men. Antimicrob. Agents Chemother. 52:3478-3483.
6. Cirillo I, et al. 2009. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. J. Clin. Pharmacol. 49:798-806.
7. Crandon JL, Bulik CC, Nicolau DP. 2009. In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:4352-4356.
8. EUCAST. 2011. Breakpoint tables for interpretation of MICs and zone diameters. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden. http://www.eucast.org/fileadmin/src/media/PDFs /EUCAST-files/Disk-test-documents/EUCAST-breakpoints-v1.3-pdf.
9. European Medicines Agency. 2008. CHMP assessment report for Doribax. Procedure no. EMEA/H/C/000891. Committee for Medicinal Products for Human Use, European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/ docs/en-GB/document-library /EPAR---Public-assessment-report/human/000891/ WC500037151.pdf.
10. European Medicines Agency. 2008. Annex 1: summary of product characteristics. European Public Assessment Report, European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en -GB/document-library/ EPAR---Product-Information/human/000891 /WC500037148.pdf.
11. Farrell D, Moet G, Sader H, Putman S, Jones R. 2010. Antimicrobial activity of doripenem against clinical pathogens from Europe, 2009, abstr. P1874. Abstr. 20th Eur. Congr. of Clin. Microbiol. Infect. Dis., Vienna, Austria, 10 to 13 April 2010.
12. Hilliard JJ, et al. 2011. Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model. Antimicrob. Agents Chemother. 55:836-844.
13. Hori T, Nakano M, Kimura Y, Murakami K. 2006. Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. In Vivo 20:91-96. (Pubitemid 43103722)
14. Ikawa K, Morikawa N, Ikeda K, Ohge H, Sueda T. 2008. Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation. Diagn. Microbiol. Infect. Dis. 62:292-297.
15. Jean SS, et al. 2010. In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units: nationwide data from the SMART Programme. Eur. J. Clin. Microbiol. Infect. Dis. 29:471-475.
16. Joukhadar C, Derendorf H, Muller M. 2001. Microdialysis. A novel tool for clinical studies of anti-infective agents. Eur. J. Clin. Pharmacol. 57: 211-219. (Pubitemid 32662465)
17. Katsube T, Yamano Y, Yano Y. 2008. Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. J. Pharm. Sci. 97:1606-1614.
18. Katsube T, Yano Y, Wajima T, Yamano Y, Takano M. 2010. Pharmacokinetic/pharmacodynamic modeling and simulation to determine effective dosage regimens for doripenem. J. Pharm. Sci. 99: 2483-2491.
19. Lammens C, et al. 2010. In vitro activity of doripenem, a new carbapenem, against recent Gram negative clinical isolates from Belgium, abstr. P1620. Abstr. 20th Eur. Congr. Clin. Microbiol. Infect. Dis., Vienna, Austria, April 2010.
20. Lönnroth P, Jansson PA, Smith U. 1987. A microdialysis method allowing characterization of intercellular water space in humans. Am. J. Physiol. 253:E228-E231.
21. Müller M, et al. 1996. Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. Antimicrob. Agents Chemother. 40:2703-2709. (Pubitemid 26404329)
22. Müller M, et al. 1995. Application of microdialysis to clinical pharmacokinetics in humans. Clin. Pharmacol. Ther. 57:371-380.
23. Paterson DL, Depestel DD. 2009. Doripenem. Clin. Infect. Dis. 49: 291-298.
24. Samtani MN, Flamm R, Kaniga K, and Nandy P. 2010. Pharmacokinetic- pharmacodynamic- model-guided doripenem dosing in critically ill patients. Antimicrob. Agents Chemother. 54:2360-2364.
25. Van Wart SA, Andes DR, Ambrose PG, Bhavnani SM. 2009. Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn. Microbiol. Infect. Dis. 63:409-414.
26. Yamada Y, et al. 2010. Penetration of doripenem into prostatic tissue following intravenous administration in prostatectomy patients. Int. J. Antimicrob. Agents 35:504-506.